circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Activate. Inhibit. Empower. Changing the Course of Cardiovascular Disease, A Cytokinetics Virtual Investor and Analyst Day
    Jul 15, 2020 5:30 AM EDT

    Activate. Inhibit. Empower. Changing the Course of Cardiovascular Disease, A Cytokinetics Virtual Investor and Analyst Day
    Jul 15, 2020 5:30 AM EDT
  • Webcast
    X Goldman Sachs 41st Annual Global Healthcare Conference
    Jun 10, 2020 4:40 PM EDT

    Goldman Sachs 41st Annual Global Healthcare Conference
    Jun 10, 2020 4:40 PM EDT
  • Webcast
    X Cytokinetics, Inc. Annual Shareholder Meeting
    May 13, 2020 10:30 AM PDT

    Cytokinetics, Inc. Annual Shareholder Meeting
    May 13, 2020 10:30 AM PDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July 15, 2020 from 8:30 AM to 11:30 AM ET . Members of Cytokinetics’ senior management will be joined by
Toggle Summary Cytokinetics to Participate In Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. ,, June 08, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Goldman Sachs 41 st Annual Global Healthcare
Toggle Summary Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. , and WASHINGTON , May 27, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2020 ALS Roundtables and ALS Focus, a
Toggle Summary FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , May 8, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S.